Biotech RadarJobs updated

COMPANY

REVOLUTION Medicines

HQ: Redwood City, CA source · revmed.com ↗

FDA-approved therapeutic company Clinical Phase 3

Location: Redwood City, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Pancreatic Cancer Pancreatic Cancer Metastatic PDAC - Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma Pancreatic Adenocarcinoma Metastatic Pancreatic Adenocarcinoma Pancreatic Adenosquamous Carcinoma Non-Small Cell Lung Cancer NSCLC CRC Colorectal Cancer Lung Cancer (NSCLC) NSCLC (Non-small Cell Lung Cancer) NSCLC (Non-small Cell Lung Carcinoma) NSCLC (Advanced Non-small Cell Lung Cancer) Resectable Pancreatic Ductal Adenocarcinoma (PDAC) Resected Pancreatic Adenocarcinoma Gastrointestinal Cancer Metastatic Pancreatic Ductal Adenocarcinoma Metastatic Pancreas Adenocarcinoma Non-Small Cell Lung Cancer NSCLC Non-Squamous Non Small Cell Lung Cancer Metastatic NSCLC - Non-Small Cell Lung Cancer Metastatic Non-Squamous Non-Small Cell Lung Cancer KRAS, NRAS, HRAS-mutated NSCLC RAS G12D-mutated NSCLC RMC-6236 RMC-9805 RMC-4630 RMC-6291 RMC-5127

$3.1BRaised (2 yrs)20Trials (company is sponsor)1FDA records (2 yrs)

Timeline

  1. Trial start Phase 3: Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma source ↗
  2. FDA FDA New drug/biologic (novel): RASONQUE (daraxonrasib) — NDA220910, Aug 26, 2026. Applicant at approval: Revolution Medicines, Incorporated. source ↗
  3. Trial start Phase 3: Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC source ↗
  4. Trial start Phase 3: Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute source ↗
  5. Raise Follow-on offering: $2.2B (total, as published), announced Apr 17, 2026. Source: company release on GlobeNewswire. source ↗
  6. Trial start Phase 3: Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma source ↗
  7. Trial start Phase 1/Phase 2: Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors source ↗
  8. Trial start Phase 1: Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors source ↗
  9. Trial start Phase 3: Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) source ↗
  10. Trial start Phase 3: Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) source ↗
  11. Raise Follow-on offering: $862.5M (total, as published), announced Dec 5, 2024. Source: company release on GlobeNewswire. source ↗
  12. Trial start 3: Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) source ↗
  13. Trial start Phase 1/Phase 2: Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors source ↗
  14. Trial start Phase 1/Phase 2: Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC source ↗
  15. Trial start Phase 1/Phase 2: Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors source ↗
  16. Trial start Phase 1: Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors source ↗
  17. Trial start Phase 1: Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors source ↗
  18. Trial start Phase 1/Phase 2: Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS source ↗
  19. Trial start Phase 2: Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies source ↗
  20. Trial start Phase 1: Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors source ↗
  21. Trial start Phase 1/Phase 2: Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC source ↗
  22. Trial start Phase 1: Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $3.1B. Last 2 years.

Clinical trials (lead sponsor) 20

RecordTitlePhaseStatusStartPrimary completion
NCT07491445Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaPhase 3RecruitingMar 9, 20262028-06 (estimated)
NCT06881784Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)Phase 3RecruitingMay 6, 2025Dec 1, 2027 (estimated)
NCT07621718Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )Phase 3RecruitingMay 22, 2026Dec 30, 2028 (estimated)
NCT07252232Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)Phase 3RecruitingDec 15, 2025May 10, 2029 (estimated)
NCT06128551Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsPhase 1/Phase 2RecruitingNov 14, 20232028-12 (estimated)
NCT06445062Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsPhase 1/Phase 2RecruitingMay 24, 2024Sep 30, 2028 (estimated)
NCT07349537Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid TumorsPhase 1RecruitingJan 8, 20262028-04 (estimated)
NCT07805954Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic AdenocarcinomaPhase 3RecruitingAug 28, 20262029-03 (estimated)
NCT07573215Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic AdenocarcinomaNot listedApproved for marketingNot listedNot listed
NCT07777822Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLCPhase 3RecruitingAug 14, 20262029-10 (estimated)
NCT07397338Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid TumorsPhase 1/Phase 2RecruitingJan 30, 20262029-05 (estimated)
NCT06162221Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCPhase 1/Phase 2RecruitingJan 18, 20242027-06 (estimated)
NCT06040541Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsPhase 1RecruitingSep 7, 2023Dec 31, 2026 (estimated)
NCT06625320Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)3Active, not recruitingOct 16, 20242026-06 (estimated)
NCT05462717Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid TumorsPhase 1Active, not recruitingSep 19, 2022Mar 31, 2027 (estimated)
NCT05379985Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASPhase 1/Phase 2RecruitingMay 31, 2022May 31, 2027 (estimated)
NCT05054725Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard TherapiesPhase 2CompletedDec 30, 2021Jul 3, 2024 (actual)
NCT04774952Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid TumorsPhase 1CompletedApr 7, 2021May 6, 2024 (actual)
NCT03989115Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLCPhase 1/Phase 2CompletedJul 2, 2019Feb 8, 2022 (actual)
NCT03634982Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid TumorsPhase 1Unknown status (ClinicalTrials.gov)Sep 28, 2018Mar 31, 2023 (estimated)

FDA records (last 2 years)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback